Lv21
180 积分 2026-05-15 加入
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial
4小时前
已完结
成人2型糖尿病口服降糖药联合治疗专家共识（2025版）
8小时前
已完结
Orforglipron在2型糖尿病与肥胖治疗中的应用进展
2天前
已完结
遗传性血管性水肿与获得性血管性水肿的诊断及治疗进展
7天前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
21天前
已完结
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
21天前
已完结
1990-2021年全球背景下中国2型糖尿病流行情况、疾病负担和危险因素分析及预测研究
26天前
已完结
中国成人短肠综合征诊疗专家共识(2026版)
28天前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
1个月前
已完结
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
1个月前
已完结
β-内酰胺抗生素作用机制的研究进展
1个月前
已采纳
皖公网安备34019202002308
